

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptal5351xs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	2	Apr 08	Web Page URLs for STN Seminar Schedule - N. America
NEWS	3	Apr 09	"Ask CAS" for self-help around the clock
NEWS	4	Apr 09	BEILSTEIN: Peload and Implementation of a New Subject Area
NEWS	5	Apr 13	SDB will be removed from STN
NEWS	6	Apr 22	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	7	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	8	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	9	Jun 03	Federal Research in Progress (FEDRIP) now available
NEWS	10	Jun 10	New e-mail delivery for search results now available
NEWS	11	Jun 10	MEDLINE Pelcad
NEWS	12	Jul 02	PCTFULL has been reloaded
NEWS	13	Jul 02	FOREGE nc longer contains STANDARDS file segment
NEWS	13	Jul 02	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 09	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 04	CANCERLIT reload
NEWS	17	Aug 04	PHARMAMarketLetter (PHAFMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 13	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 13	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 13	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JATIIC has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTERNET			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:46:32 ON 25 SEP 2002

=> FIL BIOSIS SCISEARCH CA MEDLINE USPATFULL
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	0.42	0.42

FILE 'BIOSIS' ENTERED AT 09:47:32 ON 25 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 09:47:32 ON 25 SEP 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CA' ENTERED AT 09:47:32 ON 25 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:47:32 ON 25 SEP 2002

FILE 'USPATFULL' ENTERED AT 09:47:32 ON 25 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (phospholip? (2n) scrambl? (2n) 1) or plscrl or hmmtralb
L1 55 (PHOSPHOLIP? (2N) SCRAMBL? (2N) 1) OR PLSCR1 OR HMMTRALB

=> s antisense or (complement? (2n) oligonucl?)
L2 103714 ANTISENSE OR (COMPLEMENT? (2N) OLIGONUCL?)

=> s l1 and l2
L3 ? L1 AND L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 7 DUP REM L3 (2 DUPLICATES REMOVED)

=> d 14 1-7 ibib absd
'ABSD' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUILE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib abs

L4 ANSWER 1 OF 7 USPATFULL
ACCESSION NUMBER: 2001157099 USPATFULL
TITLE: 32621, novel human phospholipid scramblase-like
molecules and uses thereof
INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED
STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081698	A1	20020627
APPLICATION INFO.:	US 2001-795036	A1	20010226 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-186234P	20000229 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel human phospholipid scramblase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length human phospholipid scramblase-like proteins, the invention further provides isolated human phospholipid scramblase-like fusion proteins, antigenic peptides, and anti-human phospholipid scramblase-like antibodies. The invention also provides human phospholipid scramblase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a human phospholipid scramblase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 7 USPATFULL
ACCESSION NUMBER: 2002-99407 USPATFULL
TITLE: Nucleic acids, proteins and antibodies
INVENTOR(S): Fosen, Craig A., Laytinsville, MD, UNITED STATES
Fubun, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002053308	A1	20020502
APPLICATION INFO.:	US 2001-925301	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124270P	19990312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	30577	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presence of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosis tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The

present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 7 USPATFULL

ACCESSION NUMBER: 2002:72597 USPATFULL
TITLE: Compositions, kits, and methods for identification and modulation of T helper-1 and T helper-2 cells and diseases associated therewith
INVENTOR(S): Hanrahan, Catherine F., London, UNITED KINGDOM
Feldmann, Marc, London, UNITED KINGDOM
Trepicchio, William L., Andover, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002039734	A1	20020404
APPLICATION INFO.:	US 2001-860655	A1	20010517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205204P	20000518 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	5313	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions, kits and methods for identifying, detecting, and modulating the differentiation, growth, and/or maturation of Th1 or Th2 cells. The invention further relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating a Th1- or Th2-associated condition. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of a Th1 or Th2 cell or Th1- or Th2-associated condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 7 USPATFULL

ACCESSION NUMBER: 2002:66885 USPATFULL
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
INVENTOR(S): Trepicchio, William L., Andover, MA, UNITED STATES
Destreicher, Judith L., Portsmouth, NH, UNITED STATES
Dorner, Andrew J., Lexington, MA, UNITED STATES
Krueger, James G., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037538	A1	20020328
APPLICATION INFO.:	US 2001-892400	A1	20010509 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-203087P	20000509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	47	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 6087

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating psoriasis. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 7 BICSIIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. DUPLICATE 1
ACCESSION NUMBER: 2002:317709 BIOSIS
DOCUMENT NUMBER: PFEV100200317709
TITLE: Effect of MmTPA1b/phospholipid scramblase 1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes.
AUTHOR(S): Nakamaki, Tsuyoshi; Okabe-Kado, Junko; Yamamoto-Yamaguchi, Yuki; Hino, Ken-ichiro; Tomiyasu, Shigeru; Honma, Yoshiro; Kasukabe, Takashi (1)
CORPORATE SOURCE: (1) Saitama Cancer Center Research Institute, 818 Komuro, Ina, Saitama, 362-0806: kasukabe@cancer-c.pref.saitama.jp Japan
SOURCE: Experimental Hematology (Charlottesville), (May, 2002) Vol. 30, No. 5, pp. 421-429. <http://www.iseh.org/journal/>. print.
ISSN: 0301-472X.

DOCUMENT TYPE: Article
LANGUAGE: English

AB Objective. We previously cloned a human normal counterpart (MmTPA1b/**phospholipid scramblase 1**) of the mouse leukemogenesis-associated gene MmTPA1a. MmTPA1b gene expression was increased during differentiation of human monoblastic leukemia U937 cells using some differentiation inducers but not 1alpha,25-dihydroxyvitamin D3 (a typical monocytic differentiation inducer). To further elucidate the role of human MmTPA1b gene expression in the differentiation of myelogenous leukemia cells, we measured MmTPA1b gene expression in several myeloid leukemia cell lines and primary leukemia cells. Materials and Methods. The expression of MmTPA1b mRNA was determined by semiquantitative reverse transcriptase polymerase chain reaction. Results. Expression of the MmTPA1b gene was markedly induced during granulocytic differentiation of promyelocytic leukemia NB4 and HT93 cells induced by all-trans retinoic acid (ATRA). The level of MmTPA1b mRNA was significantly increased during differentiation toward granulocytes, but not monocytes/macrophages, in bipotential myeloid leukemia HL-60 cells. The level of MmTPA1 mRNA was not increased during erythroid differentiation induced by hemin in erythroid leukemia K562 and HEL cells or during megakaryocytic differentiation induced by 12-O-tetradecanoylphorbol-13-acetate in K562 cells. Expression of the MmTPA1b gene also was not induced when apoptosis of NB4 cells was induced by antileukemic drugs. ATRA-induced differentiation of **antisense** MmTPA1b-transfected NB4 cells was significantly suppressed. On the other hand, ATRA induced the differentiation of MmTPA1b-transfected NB4 cells more efficiently than that of mock-transfected cells. MmTPA1b mRNA also was clearly induced in ATRA-treated primary acute promyelocytic leukemia cells during granulocytic differentiation. Conclusion. MmTPA1b mRNA was specifically induced during granulocytic differentiation of acute promyelocytic leukemia cells and was associated with induction of their differentiation.

L4 ANSWER 6 OF 7 USPATFULL
ACCESSION NUMBER: 2001:40250 USPATFULL
TITLE: Methods and compositions to alter the cell surface expression of phosphatidylserine and other

INVENTOR(S): clot-promoting plasma membrane phospholipids
 Wiedmer, Therese, Mequon, WI, United States
 Sims, Peter J., Mequon, WI, United States
 PATENT ASSIGNEE(S): The Blood Center Research Foundation, Milwaukee, WI,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6204035	B1	20010320
APPLICATION INFO.:	US 1997-949246		19971010 (8)
RELATED APFLN. INFO.:	Continuation-in-part of Ser. No. US 1997-790186, filed on 29 Jan 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sisson, Bradley L.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Quarles & Brady		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	2158		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein preparation that mediates Ca^{sup.+2} transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 7 USPATFULL
 ACCESSION NUMBER: 2001:4884 USPATFULL
 TITLE: DNA encoding phospholipid scramblase
 INVENTOR(S): Wiedmer, Therese, Mequon, WI, United States
 Sims, Peter J., Mequon, WI, United States
 PATENT ASSIGNEE(S): Blood Center Research Foundation, Milwaukee, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172210	B1	20010109
APPLICATION INFO.:	US 1997-790186		19970129 (8)
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hendricks, Keith D.		
LEGAL REPRESENTATIVE:	Quarles & Brady LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1372		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An protein preparation that mediates Ca^{sup.+2} transbilayer movement of phospholipid is disclosed. A recombinantly engineered DNA sequence encoding the protein, an inhibitor of the protein activity, genetically engineered cells with altered protein activity, and therapeutic methods are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.04	30.46

STN INTERNATIONAL LOGOFF AT 09:50:27 ON 25 SEP 2002